Tag: Oncolytic virotherapy

Vyriad, Merck to launch phase 1 study of immuno oncology drugs Voyager-V1 and avelumab

pharmanewsdaily- July 18, 2018

Vyriad, a US biotech company, has entered into a collaboration with Germany-based Merck to launch a phase 1 trial of their immuno oncology drugs combination ... Read More